1. Histone deacetylase inhibitors suppress coxsackievirus B3 growth in vitro and myocarditis induced in mice.
- Author
-
Shim SH, Park JH, Ye MB, and Nam JH
- Subjects
- Animals, Coxsackievirus Infections, Enterovirus B, Human genetics, Enterovirus Infections enzymology, Enterovirus Infections genetics, Enterovirus Infections virology, HeLa Cells, Histone Deacetylase 2 genetics, Histone Deacetylase 2 metabolism, Humans, Male, Mice, Mice, Inbred BALB C, Myocarditis enzymology, Myocarditis genetics, Myocarditis virology, Enterovirus B, Human drug effects, Enterovirus B, Human physiology, Enterovirus Infections prevention & control, Histone Deacetylase Inhibitors administration & dosage, Hydroxamic Acids administration & dosage, Myocarditis prevention & control, Virus Replication
- Abstract
Unlabelled: Clinical importance of myocarditis, predominantly caused by coxsackievirus B3 (CVB3), is recently rising. However, a detailed mechanism of pathogenesis of CVB3 myocarditis still needs to be clarified. Recently, it has been reported that histone modifications including acetylation are involved in coxsackievirus replication. To examine whether the CVB3 replication requires histone acetylation, histone deacetylase (HDAC) inhibitors were employed. We found that the HDAC2 activity increased in virus-infected cells at 12 hrs p.i. and that HDAC inhibitors suppressed the virus replication in vitro. This suggests that the HDAC2 activity may be required for the virus replication. Eventually, a HDAC inhibitor trichostatin A protected against CVB3-induced myocardial injury in vivo. Our results suggest that HDAC may be a novel therapeutic target for treating viral myocarditis., Keywords: coxsackievirus B3; histone acetyltransferase; histone deacetylase; HDAC inhibitors, trichostatin A; apicidin; valproic acid; shRNA; myocarditis; mouse.
- Published
- 2013
- Full Text
- View/download PDF